Ibio Inc (IBIO) 0.69 $IBIO
ACHN, IBIO, CRAY, IBCA, QLTY, PIY Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Sep 16, 6:08AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Achillion Pharmaceuticals Inc (NASDAQ:ACHN), Ibio Inc (NYSE:IBIO), Cray Inc (NASDAQ:CRAY), Intervest Bancshares Corp (NASDAQ:IBCA), Quality Distribution Inc (NASDAQ:QLTY), Preferredplus Trust Series Czn 1 (NYSE
IY) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
iBio names Dr Thomas A. Medsger Jr to clinical advisory board
M2 - Wed Sep 03, 5:56AM CDT
Biotechnology company iBio (NYSE MKT:IBIO) revealed on Tuesday the addition of Dr Thomas A. Medsger Jr, MD to its clinical advisory board.
Dr. Thomas A. Medsger Jr. Joins iBio Clinical Advisory Board
Marketwire - Tue Sep 02, 7:32AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of biotechnology for developing and manufacturing plant-made pharmaceutical products, has appointed Thomas A. Medsger Jr., M.D., to its clinical advisory board.
Yellow Fever - Therapeutics Pipeline Review, H2 2014 - 6 Companies & 5 Drug Profiles
M2 - Mon Sep 01, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x2n27t/yellow_fever) has announced the addition of the "Yellow Fever - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Yellow Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Yellow Fever and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Yellow Fever - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Yellow Fever and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Yellow Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Yellow Fever pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Panacea Biotec Limited - Janssen Pharmaceuticals, Inc. - NewLink Genetics Corporation - iBio, Inc. - Arbovax, Inc. - Themis Bioscience GmbH Drug Profiles - Flaviviruses Infection Vaccine - LCTA-949 - DiTU - BG-323 - yellow fever [YF-17D] (polyvalent) vaccine For more information visit http://www.researchandmarkets.com/research/x2...llow_fever
iBio Receives European Patent Allowances for Protein Expression Technology
Marketwire - Thu Aug 28, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, received notices of intention to grant for two European patent applications claiming novel protein expression technologies.
iBio Enters Into $10 Million Common Stock Purchase Agreement With Aspire Capital
Marketwire - Tue Aug 26, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, today announced it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC. Within two business days of approval of the transaction by the NYSE MKT, Aspire Capital will complete an initial purchase of 1,136,354 shares of common stock at $0.44 per share, the closing sale price of iBio's common stock on the NYSE MKT on the business day prior to entry into the purchase agreement with Aspire Capital, for proceeds of $500,000. After the SEC declares a registration statement effective relating to the transaction, Aspire Capital has committed to purchase up to $9.5 million in additional shares of common stock over a 24 month period. No warrants are associated with this agreement.
GBLI, IBIO, HBOS, CASS, CLMS Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Aug 18, 7:16AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Global Indemnity PLC (NASDAQ:GBLI), Ibio Inc (NYSE:IBIO), Heritage Financial Group Inc (NASDAQ:HBOS), CASS INFORMATION SYSTEMS, INC. (NASDAQ:CASS), Calamos Asset Management Inc (NASDAQ:CLMS) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
iBio Forms Marketing Collaboration With Kanematsu Chemicals Corporation to Target Japanese Market
Marketwire - Thu Aug 14, 7:32AM CDT
iBio, Inc. (NYSE MKT: IBIO), and Kanematsu Chemicals Corporation, part of Kanematsu Corporation (TSE: 8020), have entered into a collaboration agreement under which Kanematsu Chemicals Corporation will market the novel iBioLaunch(TM) platform in Japan.
iBio Appoints Another IPF Expert, Dr. J. Terrill Huggins, to Clinical Advisory Board
Marketwire - Wed Jul 30, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has appointed J. Terrill Huggins, M.D. to its clinical advisory board. The board of science and medical experts is assisting iBio in its clinical and product strategy.
iBio names Dr Richard M. Silver to clinical advisory board
M2 - Tue Jul 22, 8:30AM CDT
Plant biotechnology company iBio (NYSE MKT:IBIO) revealed on Monday the addition of Dr Richard M. Silver, MD to its clinical advisory board.
iBio Appoints Dr. Richard M. Silver to Clinical Advisory Board
Marketwire - Mon Jul 21, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has appointed Richard M. Silver, M.D. to its recently formed clinical advisory board.
iBio elects Dr Timothy Blackwell as clinical advisory member
M2 - Thu Jul 17, 7:27AM CDT
Plant-based biotechnology company iBio (NYSE MKT:IBIO) disclosed on Wednesday the addition of Timothy Blackwell MD to its newly formed clinical advisory board.
iBio Appoints Dr. Timothy Blackwell to New Clinical Advisory Board
Marketwire - Wed Jul 16, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has appointed Timothy Blackwell, M.D. to its newly formed clinical advisory board.
Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lpdgx/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alpha- Antitrypsin Deficiency - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sangamo BioSciences, Inc. - Grifols, S.A. - rEVO Biologics - International Stem Cell Corporation - Kamada Ltd. - Dicerna Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - Applied Genetic Technologies Corporation - Intrexon Corporation - Polyphor Ltd. - iBio, Inc. - OrphageniX, Inc. - Carolus Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/4lpdgx/alpha
Yellow Fever - Pipeline Review, H1 2014
M2 - Thu Jun 26, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l3x72t/yellow_fever) has announced the addition of the "Yellow Fever - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Yellow Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Yellow Fever and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Yellow Fever - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Yellow Fever pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Arbovax, Inc. - Crucell N.V. - Janssen Pharmaceuticals, Inc. - Medigen, Inc. - Panacea Biotec Limited - Themis Bioscience GmbH - iBio, Inc. For more information visit http://www.researchandmarkets.com/research/l3...llow_fever
iBio Expands Commercial Collaboration With Bio-Manguinhos and Fraunhofer
Marketwire - Wed Jun 18, 1:23AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, amended its multiproduct license and collaboration agreement with Brazil's Bio-Manguinhos/Fiocruz and the Fraunhofer USA Center for Molecular Biotechnology to enable expansion of joint work on an iBioLaunch(TM)-produced recombinant yellow fever vaccine and other products.
iBio Receives Patent Allowances for Pandemic Influenza Therapeutics
Marketwire - Thu Mar 27, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the allowance of two U.S. patents for monoclonal antibodies targeting influenza.
Global Biosimilars Market 2014-2018: Patent Expirations and More
M2 - Wed Mar 05, 11:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/jggmhc/global) has announced the addition of the "Global Biosimilars Market 2014-2018" report to their offering. The analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing number of patent expirations. The Global Biosimilars Market has also been witnessing the outsourcing of biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market. Key vendors dominating this space include Biocon Ltd., Hospira Inc., Mylan Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., 3SBio Inc., and Celltrion Inc. Other vendors mentioned in the report are Actavis plc, Amgen Inc., AstraZeneca plc, Baxter International Inc., Biogen Idec Inc., Bioton S.A., Boehringer Ingelheim GmbH, Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Emcure Pharmaceuticals Ltd., GE Healthcare Ltd., GeneScience Pharmaceuticals Co. Ltd., GlaxoSmithKline plc, JCR Pharmaceuticals Co. Ltd., iBio Inc., LG Life Sciences Co. Ltd., Merck & Co. Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Samsung Biologics Co. Ltd., Sanofi S.A., and Wockhardt Ltd. Commenting on the report, an analyst from the team said: The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. For more information visit http://www.researchandmarkets.com/research/jggmhc/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
iBio to Present at the 26th Annual ROTH Conference on March 10, 2014
Marketwire - Tue Mar 04, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, has been invited to present at the 26th Annual ROTH Conference being held March 10-12, 2014 at the Ritz Carlton in Dana Point, California.
PlayStation®4 (PS4(TM)) Sales Surpass 6.0 Million Units Worldwide In Less Than 4 Months Since Launch, Rapidly Popularizes A New Way To Enjoy Social Interaction Through Gaming
PR Newswire - Tue Mar 04, 1:18AM CST
Sony Computer Entertainment Inc. (SCE) today announced that the PlayStation®4 (PS4(TM)) computer entertainment system has cumulatively sold through more than 6.0 million units*1 globally as of March 2, 2014 (JST). This also includes the 370,000 units sold through in Japan since its launch on February 22.
ACHN, IBIO, CRAY, IBCA, QLTY, PIY Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Sep 16, 6:08AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Achillion Pharmaceuticals Inc (NASDAQ:ACHN), Ibio Inc (NYSE:IBIO), Cray Inc (NASDAQ:CRAY), Intervest Bancshares Corp (NASDAQ:IBCA), Quality Distribution Inc (NASDAQ:QLTY), Preferredplus Trust Series Czn 1 (NYSE
IY) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: iBio names Dr Thomas A. Medsger Jr to clinical advisory board
M2 - Wed Sep 03, 5:56AM CDT
Biotechnology company iBio (NYSE MKT:IBIO) revealed on Tuesday the addition of Dr Thomas A. Medsger Jr, MD to its clinical advisory board.
Dr. Thomas A. Medsger Jr. Joins iBio Clinical Advisory Board
Marketwire - Tue Sep 02, 7:32AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of biotechnology for developing and manufacturing plant-made pharmaceutical products, has appointed Thomas A. Medsger Jr., M.D., to its clinical advisory board.
Yellow Fever - Therapeutics Pipeline Review, H2 2014 - 6 Companies & 5 Drug Profiles
M2 - Mon Sep 01, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x2n27t/yellow_fever) has announced the addition of the "Yellow Fever - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Yellow Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Yellow Fever and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Yellow Fever - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Yellow Fever and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Yellow Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Yellow Fever pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Panacea Biotec Limited - Janssen Pharmaceuticals, Inc. - NewLink Genetics Corporation - iBio, Inc. - Arbovax, Inc. - Themis Bioscience GmbH Drug Profiles - Flaviviruses Infection Vaccine - LCTA-949 - DiTU - BG-323 - yellow fever [YF-17D] (polyvalent) vaccine For more information visit http://www.researchandmarkets.com/research/x2...llow_fever
iBio Receives European Patent Allowances for Protein Expression Technology
Marketwire - Thu Aug 28, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, received notices of intention to grant for two European patent applications claiming novel protein expression technologies.
iBio Enters Into $10 Million Common Stock Purchase Agreement With Aspire Capital
Marketwire - Tue Aug 26, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, today announced it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC. Within two business days of approval of the transaction by the NYSE MKT, Aspire Capital will complete an initial purchase of 1,136,354 shares of common stock at $0.44 per share, the closing sale price of iBio's common stock on the NYSE MKT on the business day prior to entry into the purchase agreement with Aspire Capital, for proceeds of $500,000. After the SEC declares a registration statement effective relating to the transaction, Aspire Capital has committed to purchase up to $9.5 million in additional shares of common stock over a 24 month period. No warrants are associated with this agreement.
GBLI, IBIO, HBOS, CASS, CLMS Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Aug 18, 7:16AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Global Indemnity PLC (NASDAQ:GBLI), Ibio Inc (NYSE:IBIO), Heritage Financial Group Inc (NASDAQ:HBOS), CASS INFORMATION SYSTEMS, INC. (NASDAQ:CASS), Calamos Asset Management Inc (NASDAQ:CLMS) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
iBio Forms Marketing Collaboration With Kanematsu Chemicals Corporation to Target Japanese Market
Marketwire - Thu Aug 14, 7:32AM CDT
iBio, Inc. (NYSE MKT: IBIO), and Kanematsu Chemicals Corporation, part of Kanematsu Corporation (TSE: 8020), have entered into a collaboration agreement under which Kanematsu Chemicals Corporation will market the novel iBioLaunch(TM) platform in Japan.
iBio Appoints Another IPF Expert, Dr. J. Terrill Huggins, to Clinical Advisory Board
Marketwire - Wed Jul 30, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has appointed J. Terrill Huggins, M.D. to its clinical advisory board. The board of science and medical experts is assisting iBio in its clinical and product strategy.
iBio names Dr Richard M. Silver to clinical advisory board
M2 - Tue Jul 22, 8:30AM CDT
Plant biotechnology company iBio (NYSE MKT:IBIO) revealed on Monday the addition of Dr Richard M. Silver, MD to its clinical advisory board.
iBio Appoints Dr. Richard M. Silver to Clinical Advisory Board
Marketwire - Mon Jul 21, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has appointed Richard M. Silver, M.D. to its recently formed clinical advisory board.
iBio elects Dr Timothy Blackwell as clinical advisory member
M2 - Thu Jul 17, 7:27AM CDT
Plant-based biotechnology company iBio (NYSE MKT:IBIO) disclosed on Wednesday the addition of Timothy Blackwell MD to its newly formed clinical advisory board.
iBio Appoints Dr. Timothy Blackwell to New Clinical Advisory Board
Marketwire - Wed Jul 16, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has appointed Timothy Blackwell, M.D. to its newly formed clinical advisory board.
Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lpdgx/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alpha- Antitrypsin Deficiency - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sangamo BioSciences, Inc. - Grifols, S.A. - rEVO Biologics - International Stem Cell Corporation - Kamada Ltd. - Dicerna Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - Applied Genetic Technologies Corporation - Intrexon Corporation - Polyphor Ltd. - iBio, Inc. - OrphageniX, Inc. - Carolus Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/4lpdgx/alpha
Yellow Fever - Pipeline Review, H1 2014
M2 - Thu Jun 26, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l3x72t/yellow_fever) has announced the addition of the "Yellow Fever - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Yellow Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Yellow Fever and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Yellow Fever - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Yellow Fever pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Arbovax, Inc. - Crucell N.V. - Janssen Pharmaceuticals, Inc. - Medigen, Inc. - Panacea Biotec Limited - Themis Bioscience GmbH - iBio, Inc. For more information visit http://www.researchandmarkets.com/research/l3...llow_fever
iBio Expands Commercial Collaboration With Bio-Manguinhos and Fraunhofer
Marketwire - Wed Jun 18, 1:23AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, amended its multiproduct license and collaboration agreement with Brazil's Bio-Manguinhos/Fiocruz and the Fraunhofer USA Center for Molecular Biotechnology to enable expansion of joint work on an iBioLaunch(TM)-produced recombinant yellow fever vaccine and other products.
iBio Receives Patent Allowances for Pandemic Influenza Therapeutics
Marketwire - Thu Mar 27, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the allowance of two U.S. patents for monoclonal antibodies targeting influenza.
Global Biosimilars Market 2014-2018: Patent Expirations and More
M2 - Wed Mar 05, 11:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/jggmhc/global) has announced the addition of the "Global Biosimilars Market 2014-2018" report to their offering. The analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing number of patent expirations. The Global Biosimilars Market has also been witnessing the outsourcing of biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market. Key vendors dominating this space include Biocon Ltd., Hospira Inc., Mylan Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., 3SBio Inc., and Celltrion Inc. Other vendors mentioned in the report are Actavis plc, Amgen Inc., AstraZeneca plc, Baxter International Inc., Biogen Idec Inc., Bioton S.A., Boehringer Ingelheim GmbH, Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Emcure Pharmaceuticals Ltd., GE Healthcare Ltd., GeneScience Pharmaceuticals Co. Ltd., GlaxoSmithKline plc, JCR Pharmaceuticals Co. Ltd., iBio Inc., LG Life Sciences Co. Ltd., Merck & Co. Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Samsung Biologics Co. Ltd., Sanofi S.A., and Wockhardt Ltd. Commenting on the report, an analyst from the team said: The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. For more information visit http://www.researchandmarkets.com/research/jggmhc/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
iBio to Present at the 26th Annual ROTH Conference on March 10, 2014
Marketwire - Tue Mar 04, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, has been invited to present at the 26th Annual ROTH Conference being held March 10-12, 2014 at the Ritz Carlton in Dana Point, California.
PlayStation®4 (PS4(TM)) Sales Surpass 6.0 Million Units Worldwide In Less Than 4 Months Since Launch, Rapidly Popularizes A New Way To Enjoy Social Interaction Through Gaming
PR Newswire - Tue Mar 04, 1:18AM CST
Sony Computer Entertainment Inc. (SCE) today announced that the PlayStation®4 (PS4(TM)) computer entertainment system has cumulatively sold through more than 6.0 million units*1 globally as of March 2, 2014 (JST). This also includes the 370,000 units sold through in Japan since its launch on February 22.
